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Abstract
Background: We previously showed that the 10-year cardiovascular disease (CVD) risk threshold to initiate statins
for primary prevention depends on the baseline CVD risk, age, sex, and the incidence of statin-related harm
outcome and competing risk for non-CVD death. As these factors appear to vary across countries, we aimed in this
study to determine country-specific thresholds and provide guidelines a quantitative benefit-harm assessment
method for local adaptation.
Methods: For each of the 186 countries included, we replicated the benefit-harm balance analysis using an
exponential model to determine the thresholds to initiate statin use for populations aged 40 to 75 years, with no
history of CVD. The analyses took data inputs from a priori studies, including statin effect estimates (network meta-
analysis), patient preferences (survey), and baseline incidence of harm outcomes and competing risk for non-CVD
(global burden of disease study). We estimated the risk thresholds above which the benefits of statins were more likely
to outweigh the harms using a stochastic approach to account for statistical uncertainty of the input parameters.
Results: The 5th and 95th percentiles of the 10-year risk thresholds above which the benefits of statins outweigh the
harms across 186 countries ranged between 14 and 20% in men and 19–24% in women, depending on age (i.e., 90%
of the country-specific thresholds were in the ranges stated). The median risk thresholds varied from 14 to 18.5% in
men and 19 to 22% in women. The between-country variability of the thresholds was slightly attenuated when further
adjusted for age resulting, for example, in a 5th and 95th percentiles of 14–16% for ages 40–44 years and 17–21% for
ages 70–74 years in men. Some countries, especially the islands of the Western Pacific Region, had higher thresholds to
achieve net benefit of statins at 25–36% 10-year CVD risks.
Conclusions: This extensive benefit-harm analysis modeling shows that a single CVD risk threshold, irrespective of age,
sex and country, is not appropriate to initiate statin use globally. Instead, countries need to carefully determine
thresholds, considering the national or subnational contexts, to optimize benefits of statins while minimizing related
harms and economic burden.
Keywords: Statins, Primary prevention, Cardiovascular disease, Risk thresholds: benefit-harm analysis
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: henock.yebyo@uzh.ch
1Department of Epidemiology, Epidemiology, Biostatistics and Prevention
Institute, University of Zurich, Hirschengraben 84, CH-8001 Zurich,
Switzerland
Full list of author information is available at the end of the article
Yebyo et al. BMC Cardiovascular Disorders          (2020) 20:418 
https://doi.org/10.1186/s12872-020-01697-6
Introduction
Most current guidelines recommend a single thresh-
old for initiating statins for primary prevention of
cardiovascular disease (CVD) [1–3]. Irrespective of
age, sex, or other factors that influence the benefit-
harm balance of statins, common thresholds are 7.5%
or 10% 10-year risks for CVD, with or without con-
sideration of additional risk factors [1–3]. Many re-
gions, especially the low- and middle-income
countries (LMICs), usually simply adopt recommenda-
tions from the authoritative guidelines [4], such as
from the US or Europe, without a formal adaptation
process [5]. The World Health Organization (WHO)
recommends 10-year risk thresholds of 20% in high-
income, 30% in medium-income, and 40% in low-
income settings [6]; but this seems to rely entirely on
resource availability and not on the clinical benefit-
harm balance, which would suggest different thresh-
olds. Recently, the introduction of generic statins
would reduce the cost of statins [7]; yet even if costs
are too high, subsidized access to medication pro-
grams in resource-limited settings for patients with
high risk populations– as in the example of antiretro-
viral therapy for HIV–, can be devised if statins have
relevant net benefit in reducing CVD burden.
The use of a single threshold globally to initiate sta-
tins is very likely to lead to an over- and underuse of
statins in different target groups. We found in our re-
cent quantitative benefit-harm balance modelling
study for a few specific countries that age and sex
had a large influence on appropriate risk thresholds
since these factors are associated with differences in
baseline incidences of the health outcomes, both of
which impact have significant impact on the benefit-
harm balance of statins [8]. Thus, even within a
population or country, recommendations for statin
use should take into account age- and sex of target
subgroups or patients. In addition, the analyses in the
same study performed for the populations in
Switzerland, the UK, and the US showed somewhat
different thresholds, as the outcome baseline risks dif-
fer between the countries [8]. Without considering
such variations between different environments and
countries, there is a great risk that a single threshold
leads to an over- or underuse of statins. It would be
important to take local population factors into ac-
count and inform and guide national policy makers to
develop recommendations contextualized to national
or even local settings. Against this expected signifi-
cance, this study aimed to determine age- and sex-
specific CVD risk thresholds for 186 countries, par-
ticularly focusing on baseline risk variation such as
type 2 diabetes, hemorrhagic stroke, and competing
risk for non-CVD death.
Methods
Study design and population
We modelled the quantitative benefit-harm balance
using a model developed by Gail et. al. [9], which allows
to convert multiple parameters simultaneously into a
common scale that enable to judge whether the benefits
outweigh the harms or vice versa (see Additional file:
Figure S1 for analytical flow chart). The method is also
further described in detail elsewhere [8, 10]. The study
addressed statins for primary prevention of CVD for per-
sons in the general population older than 40 and youn-
ger than 75 years with no history of CVD events (but
with a certain predisposing risk) across 186 countries.
People aged 75 years or older were excluded from this
study due to limited data and treated in a separate study
[11]. We focused on low- or medium-dose statins, which
are commonly used for primary prevention [12]. While
benefit-harm profiles of specific statins differs–as previ-
ously shown –[8] we focused in this study on statins as a
class because we mainly intended to assess the extent of
threshold variation between populations. That is, the
aim here was to trigger an initiative to consider contex-
tualized recommendations for or against statins as the
function of differences in outcome risks, and not due to
differences between statins.
Selection of evidence: health outcomes, statin treatment
effects, baseline risks, and preferences
Several parameters were considered in the benefit-harm
balance modeling. The most important were statin treat-
ment effect estimates, baseline incidence of health out-
comes, patient preferences for outcomes, competing risk
for non-CVD deaths. The benefit health outcome of sta-
tins considered was CVD (fatal and non-fatal events
combined), which is commonly used as endpoint in
most guidelines and risk scores [1–3]. The adverse ef-
fects (hereinafter referred to as harms) of statins were
myopathy, hepatic and renal dysfunctions, cataracts,
hemorrhagic stroke, type 2 diabetes, all cancers, and
nausea or headache, and treatment discontinuation [12].
While stroke is generally considered a CVD event, in
this study specifically hemorrhagic stroke was considered
a harm effect as some evidence suggests [12], but ische-
mic stroke was constitutive for the benefit outcome of
CVD. We considered these predefined outcomes based
on a prior selection of outcomes and preference-eliciting
study [13]. We considered the outcomes despite the stat-
istical significance of the statin treatment effects, since
the absolute effect should be determined by the baseline
incidence of the outcomes in the general population. In
the analysis, we also considered non-CVD deaths as a
competing risk–i.e., when people die of non-CVD death
they should be deduced from the population at risk for
having CVD events or the harm outcomes. We used a
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systematic approach to identify and select the most ap-
plicable, precise, and valid estimates for treatment ef-
fects, baseline risks, and preferences of the benefit and
harm outcomes, as described below [14, 15]. Of note,
this study focused on the clinical benefit-harm balance
of statins and did not account for other factors such as
the cost of statins and associated expenses. However,
countries could further adjust thresholds depending on
the resource availability as well as the proportion of pop-
ulations at high risk for CVD, health system and health
infrastructure, affordability, etc.
We took treatment effects from our previous network
meta-analysis of statins from randomized controlled trials
(RCTs) in primary prevention population [12]. However,
comparative observational studies are also potential data
sources for providing relevant information on long-term
effects, particularly harm risks despite some inherited lim-
itations [16, 17]. We consolidated effects of statins specif-
ically for some harm outcomes from both RCTs and
observational studies using inverse variance weighted
averaging [18–20]. We used estimates that were likely to
be valid and applicable and that did not represent ex-
tremes [21]. Nonetheless, we also performed sensitivity
analyses taking estimates from RCTs only.
We previously elicited outcome preferences from po-
tential statin users using a best-worst scaling survey in
Switzerland and Ethiopia to inform this study [13]. Be-
cause people may have different values and preferences
for treatment outcomes and goals, it is important to
consider patient preferences rather than clinician per-
spectives when issuing recommendations. For example,
to some persons the risks associated with statins are per-
ceived acceptable, whereas to other risk-averse persons
statin therapy is harmful. Hence, we considered prefer-
ences from the survey that were estimated on a scale
over 0 to 1 (a higher value means that people have a
stronger preference to avoid the disease) [22]. The pref-
erences were very similar between both countries, and
thus we took the average estimates to apply across coun-
tries [13]. Indeed, the Global Burden of Disease (GBD)
study on different health outcomes also found similar
disability weights in different countries that corroborated
our assumption [23].
Age- and sex-specific baseline risks for diabetes, can-
cer, hemorrhagic stroke, and non-CVD death were ex-
tracted from the 2016 GBD estimates for the different
countries (http://ghdx.healthdata.org/gbd-results-tool)
and rates of cataracts, myopathy, and hepatic and renal
dysfunctions from other observational data (age- or
country-specific rates were not available for these harms)
[18, 24]. The GBD estimates may have limitations but
these are the most replicable and comparable data avail-
able for baseline risks. Nevertheless, our method is open
to updating when further national or sub-national data
are available to estimate more accurate thresholds that
apply to the specific populations. The input estimates
for treatment effect, preference, and outcome risks are
presented in Additional file, Tables S1 and S2.
We considered a wide, hypothetical CVD risk
spectrum (1 to 40% 10-year risk score) to determine the
threshold at which statins provide net benefit. For this
analysis it was not necessary to know which CVD risk
score to use a priori. Of course, to apply the CVD risk
thresholds from this study in practice, physicians need
to use an appropriate CVD prediction model for their
country and setting in order to determine the risk in an
individual and to recommend statins if this risk falls
above the risk thresholds determined in this study. How-
ever, it should be noted that for the application of the
thresholds, risk score for the combined CVD endpoint
(fatal and non-fatal events) must be used, not for fatal
CVD only, such as the SCORE [25].
Time horizon
We considered a 10-year horizon over which we pre-
dicted the benefit-harm balance, which is a commonly
used time horizon in most guidelines for primary pre-
vention. Other assumptions about time horizons and
temporal effects (e.g., a yearly decline in the effect of sta-
tins on harm outcomes over time) were reported in our
earlier study [8]; and, we did not duplicate such analyses
here.
Model structure
We made some adjustment to the Gail et. al. [9] model
to meet our aim for determining risk thresholds (Add-
itional file: Figure S2) [8]. The model was designed to
predict benefit and harm events in cohorts of apparently
healthy people (i.e., with no history of CVD events) aged
40 years to 75 years taking statins or not for 10 years.
The cohorts were assumed to have certain predisposing
risks for CVD; hence, we stratified a hypothetical 10-
year CVD risk spectrum, from 1 to 40% until statins
showed net benefit. We stratified the analyses by age
and sex, and country.
Analysis
Using the described model structure, we calculated the
expected prevented CVD risks and excess risks of each
harm outcome in 10,000 people over 10 years treated
with statins vs. not treated to obtain absolute expected
benefit and harm risk differences. We calculated this for
sex, age (7 age groups), and 186 countries for a range of
10-year CVD risks from 1 to 40%, using an exponential
model. The detailed statistical model was published pre-
viously and further details included in the Additional
file, method S1 [8]. For each subgroup, we then weighted
the absolute events of the outcomes by their respective
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preference values. We summed the weighted risk differ-
ences across all outcomes to yield the benefit-harm bal-
ance index in a common scale. We simulated the
analysis 100,000 times taking into account the statistical
uncertainty of each input parameter to generate a distri-
bution of the index.
From the distribution of the benefit-harm balance index,
we calculated the probability that the index was posi-
tive (more benefit than harms) across the 1% rise of the
10-year CVD risks from 1 to 40%. We defined net bene-
fit at the probability of 0.6. This means that in 60% of the
100,000 repetitions, taking statins showed net benefit
compared to not taking statins. The CVD risk level (across
the 1 to 40% risk spectrum) above which the probability
of net benefit exceeded 0.6 was the risk threshold for initi-
ating statin use for primary prevention of CVD. The rea-
son for defining the probability of net benefit at 0.6, and
not at 0.5 as is often done, was because we aimed to en-
sure some clinical relevance at the determined thresholds.
With a 0.5 probability for the index being positive, the
index is zero, on average; or, benefits of statins equal
harms. However, the 0.6 probability ensures certain abso-
lute net benefit; yet, the clinical relevance of the net benefit
can further be evaluated. Conversely, we defined net harm,
or harms outweighed benefits, if the probability for the
index being positive was less than 0.4. Probabilities be-
tween 0.4 and 0.6 represented neither net benefit nor net
harm (see Additional file: Figure S3 for additional
illustration).
Moreover, while it is important to estimate the clinical
relevance of the thresholds, the benefit-harm balance
index is difficult to interpret because it is a composite
metric resulting from multiple interaction of parameters.
As it stands, the index can be interpreted as number of
prevented fatal CVD or a poor prognosis outcome with
a maximum preference value of 1. To estimate how
many absolute events could be prevented at the calcu-
lated risk thresholds, we preferred to interpret the index
in terms of myocardial infarction (MI) events – a more
common, single, non-fatal outcome that would be more
important for clinical decision making– by dividing the
index by the preference value of the MI.
Sensitivity analysis
We conducted a sensitivity analysis to assess the impact
of including observational data. We performed the ana-
lysis, relying solely on treatment effects on harm out-
comes based on RCTs. Results of other sensitivity
analyses were published previously, including a possible
decrease in treatment effects of statins over time, pos-
sible correlation between outcomes (e.g., between CVD
and diabetes, or between diabetes and renal dysfunc-
tion), as well as different preference weights [8].
Results
10-year CVD risk thresholds for net benefit of statins
Figure 1 shows the specific thresholds for each country
where statins were more likely to provide a net benefit
with a probability of 0.6 (see Additional file: Figures S4
and S5 for further results). The 10-year CVD risk
thresholds ranged between 13 and 31% in men and 19–
36% in women of all ages and countries. The 5th and
95th percentiles of the 10-year CVD risk-thresholds of
the countries ranged from 14 to 20% in men and from
19 to 24% in women, with median varying from 14 to
18.5% in men and 19–22% in women, depending on age
from younger (40–44 years) to older people (70–74
years). After adjustment for age, the between-country
variation of the 10-year CVD risks was slightly reduced–
but still considerable– with 5th and 95th percentiles of
14–16% for ages 40–44 years and 17–21% for ages 70–
74 years in men as well as 18–21% and 20–24% in
women for the respective age groups (see detailed sub-
group estimates in the Additional file: Table S3). The
thresholds are visually illustrated in Figs. 2 and 3 across
countries globally.
While the majority of thresholds were below 21%,
some countries, such as Bahrain, Jamaica, Qatar,
Trinidad and Tobago, Brunei, and Mongolia among
others, had thresholds higher than 21% particularly
for older people. Most of the island countries of the
Western Pacific region, including Marshall Islands,
Kiribati, Fiji, Federated States of Micronesia, Tonga,
and Solomon Islands had even higher thresholds of
25–36%. On the other hand, although not materially
different from many of the other countries, the smal-
lest threshold was 13%, which occurred in most Afri-
can countries. Generally, countries in Sub-Saharan
Africa (except Lesotho, Mauritius, Swaziland, and
Botswana), countries in South America (except
Trinidad and Tobago, Jamaica, Grenada, Dominica,
and Saint Vincent and the Grenadines), and Asia (ex-
cept Mongolia, Brunei, China, and Turkmenistan for
the older people) were more likely to benefit from
statins at relatively lower risk thresholds related to
lower baseline risks of most harm outcomes.
Clinical relevance of the thresholds
The thresholds were determined ensuring that the bene-
fits exceeded the harms at least to some extent (further
illustrations, Additional file: Figure S6). The extent of
net prevented MI events were similar across countries
and between age groups at the established risk thresh-
olds, with only marginal differences between men and
women. The average prevented MI events at the deter-
mined thresholds ranged from 22 to 41 in 10,000 people
treated with statins compared to untreated over 10 years.
In other words, taking low- or moderate-dose statins
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daily for 10 years could prevent 22–41 MI events in 10,
000 adult people prescribed at the determined age- and
sex-specific baseline CVD thresholds.
Sensitivity analysis
The exclusion of observational data (i.e., taking only
RCT data) resulted in lower CVD risk thresholds for ini-
tiating statins than the base-case analysis where com-
bined effects were considered. The 5th and 95th
percentiles of the 10-year thresholds ranged from 11 to
16% (median 11–15%, depending on age) in men and
15–19.5% (median, 15–18%, depending on age) in
women (Additional file: Figure S7 and Table S4).
Discussion
We performed the first worldwide benefit-harm balance
modelling study and found that 5th and 95th percentiles
of the 10-year CVD risk-thresholds in 186 countries var-
ied from 14 to 20% in men and from 19 to 24% in
women and with median varying from 14 to 18.5% and
19–22% respectively, depending on age. While most
countries had 10-year risk thresholds below 21%, some
countries had higher thresholds. The differences in
thresholds across populations should be interpreted with
respect to baseline risks of harm outcomes and the com-
peting risk varying across countries while we kept, accord-
ing to current evidence, treatment effects and preference
values similar. The small differences in thresholds between
Fig. 1 Country-specific 10-year CVD risk thresholds in men and women and different age groups (countries grouped by region)
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men and women were due to variation in baseline risks of
the outcomes and effect estimates.
Our study showed variation in risk thresholds across
countries and, as in our earlier study [8], differences ac-
cording to age and sex. As reported previously, the higher
thresholds in the older age groups were due to the fact
that the excess harms increased with age, offsetting the
benefits of statins. The small islands countries in the west-
ern pacific region had higher risk thresholds in our study.
This was due to higher risk rates for diabetes, which
would be further increased with the use of statins that
counterbalance the possible benefit of statins in reducing
CVD events. This imply that use of a one-size-fits-all
threshold or recommendation for all populations would
lead to gross over- or underuse of statins in different pop-
ulations, depending on the distribution of the benefit and
harm risks. The threshold variation could have even been
higher if country-specific rates for all outcomes were avail-
able as well as other factors (e.g., absolute proportion of
people above the calculated risk threshold) were consid-
ered. The findings suggest the need of contextualized
thresholds that reflect national or subnational distribu-
tions of the harm risks and CVD risks, rather than import-
ing recommendations from authoritative guidelines
without proper adaptation to the local settings.
There are no well-documented approaches of how
countries determine thresholds to initiate statins. Some
countries adapted guidelines to their settings or devel-
oped their own, including Japan and Fiji (threshold
≥30% 10-year risk), but it is not clear what evidence was
considered in the customization of the guidelines. None-
theless, many countries globally, especially LMICs, do
not have clear guidelines. Those that have some sort of
guidelines, for example, Kenya, India, Fiji, South Africa,
and Brazil, are not clear about how they established their
thresholds, which seem to be adopted from guidelines
developed for other populations or settings [26–29]. For
example, the South African guideline was adapted from
the European one (probably with some changes) and thus
recommends statins for people with at least a 10-year CVD
risk of 30% (3–15% risk with additional consideration of
lipid target) [29]. However, our thresholds for this country
Fig. 2 Map of 10-year CVD risk thresholds in men of different age groups across countries
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were 14–23%, depending on age and sex. Similarly in Kenya
where statins are recommended starting at a 20% 10-year
risk, our findings showed lower thresholds, especially for
men [26]. This implies that there could be missed oppor-
tunities of preventing CVD events with statins in these pop-
ulations. On the contrary, an overuse of statins in some
settings is also possible such as in China, Brazil (for
women), the UK, and the US where a 10% or 7.5% risk is
used to start therapy (e.g., NICE or USPSTF use 10%
whereas ACC/AHA uses 7.5%), which is lower than ours
[1, 2, 6, 30]. This generally suggest the need of systematic
and quantitative approaches to establish recommendations
based on the distribution of risks, health system, infrastruc-
ture and resources.
The idea of contextualizing recommendations to dif-
ferent populations may not be new. There are initiatives
by WHO and World Heart Federation (WHF) to de-
velop roadmaps to promote development of national
policy and health systems, especially to support LMICs
in detection, treatment, and management of CVD [6].
For example, the WHO/International Society of Hyper-
tension (ISH) as well as the INTERHEART developed
risk scores for different countries and sub-regions to de-
tect people at high-risk [31, 32]. While absolute risk
scores assist in risk stratification or detection of people
at high-risk, they do not provide direct information on
who should take statins, and how possible harm risks
may influence the treatment outcome. Harms of statins
need to be weighed against the benefit to determine
even if a group of people have higher risk for CVD.
Thereby, our country-specific thresholds could serve as
a base-case–or insight– for guideline developers to ex-
tend the thresholds to more precise and tailor to
country-specific circumstances in order to harness
the benefits of statins for primary prevention and
minimize related risks and costs. It shoulld therefore
be noted that the thresholds might not be ready-to-use
for treatment decisions, because it was difficult to find
all detailed information in each country that may have
significant impact on the precision.
Fig. 3 Map of 10-year CVD risk thresholds in women of different age groups across countries
Yebyo et al. BMC Cardiovascular Disorders          (2020) 20:418 Page 7 of 10
Our thresholds show the lowest possible CVD risk levels
across countries at which statins would be more likely
to provide more benefits than harms. For example, the ab-
solute prevented MI events in 10 years were 22–41 among
hypothetical 10,000 people with a baseline CVD risk
equivalent to the calculated thresholds. However, these
events do not show the total prevented CVD events in the
general population of the different countries, which na-
tional guidelines need to take into account. That is, the
thresholds could be increased or decreased, thus can be
updated to specific settings, depending on the distribution
of CVD risk factors in populations, country’s target to re-
duce morbidity or deaths due to CVD with statin use, and
resource availability. For example, lower (or similar)
threshold in the Sub-Saharan Africa does not mean that
statin therapy would lead to higher proportion of pre-
vented CVD events in the region than high-income coun-
tries with higher thresholds. Such impact estimation is
beyond this paper, as data on the distribution of CVD risk
in the respective populations would be necessary. Our
study was directed to assisting decision-making for clinical
guideline developers. The findings were not intended to
dictate clinicians when to prescribe statins by using only
the calculated thresholds. In fact, the findings also convey
important message for individual patient decision-making
that clinicians need to evaluate the patient risks for the
potential harm outcomes (besides risk for CVD) and in-
volve patients to discuss the tradeoff between the benefits
and harms of statins.
Our findings target the general primary prevention
populations and their applicability to the diabetes popu-
lation should be considered with caution. People may
have different levels of glycemic impairment, although it
may not reach the threshold for diabetes diagnosis.
Thus, the use of statin could still raise glycaemia in dia-
betic patients, but the extent of the excessive effect is
not clear in this population. In addition, it would be dif-
ficult to understand whether the excessive risk of gly-
caemia due to statins would be negligible if patients are
under well-controlled antidiabetic treatment. On the
other hand, it is clear that diabetic patients would be
more likely to be eligible for statin treatment anyway
(with a higher 10-year baseline risk) than non-diabetic
patients, as diabetes is a strong predictor of CVD. In
general, the application of the thresholds to diabetic pa-
tients might lead to under-treatment with statins, espe-
cially in patients with well-controlled blood glucose
treatment. This can be left to the discretion of doctors
and patients, to decide whether to initiate statins, taking
into account the patients' glycemic control.
Our study is the first global benefit-harm balance
modeling study that quantitatively considers important
parameters required to determine thresholds that have
practical relevance for patients and clinical decision-
making. However, it comes with limitations such as that
we obtained country-specific baseline risks only for part
of the harm outcomes. We believe that this limitation of
not having baseline incidences for some harm outcomes,
including myopathy, renal and hepatic dysfunctions, and
cataract, for each country may have led to an underesti-
mation of the threshold variation between countries.
Specific countries could update the thresholds according
to harm outcome risks available for their specific con-
text. The debate on what evidence to consider for harms
of statins is still ongoing. The effect estimates on harms
range from almost none to large effects, depending the
sources but all data sources have their own strengths
and limitations [12, 21, 33–36]. Hence, we considered
convergent estimates, specifically for the harms, from
both RCTs and observational data that were likely to
be valid, have less bias, applicable and do not repre-
sent the extremes. We excluded observational data
and post-market surveillance sources that reported
extreme and contentious estimates [21]. Indeed, the
RCTs contributed substantially more to the conver-
gent estimates because of their higher precision; thus,
the effect estimates used for harms were rather small.
The estimates from observational studies were less
precise likely due to adjustment for several covariates,
which may have increased the standard error. In
addition, the different outcomes considered in the
analysis were defined a priori and thus considered re-
gardless of their effect size or baseline rate. For ex-
ample, hemorrhagic stroke and cancer were included
in the model, but their influence on the results was
not considerable due to the low rates or effect size of
the outcomes.
In terms of patient preferences, we took average esti-
mates from Switzerland and Ethiopia. While we elicited
preferences of the different outcomes related to statins
in socio-demographically and economically disparate
countries, Ethiopia and Switzerland [13], there may be
other factors that could have influenced the estimates
that remain unaccounted for (e.g., cost). In fact, the
GBD study also reported consistent disability weights
across countries [23], which supports our assumption of
taking the average estimates. However, it is worthwhile
to test how the preferences are affected if economic fac-
tors are taken into account. Of note, our risk thresholds
cannot be directly applied within the European Society
of Cardiology and European Atherosclerosis Society
guideline, because this clinical guideline addresses fatal
CVD, while our risk thresholds considered fatal and
non-fatal CVD events combined [25].
In summary, our worldwide map of 10-year CVD risk
thresholds above which statins for primary prevention of
CVD is likely to provide net benefit show high variation
across populations due to differences in the baseline
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incidence of some harm outcomes and the competing
risk for non-CVD death. The thresholds were also higher
in the older people than in younger adults. The findings
provide an insight for policy makers and guideline devel-
opers to consider contextual data to revise their guide-
lines on the use of statins, and adapt eligibility criteria
for their specific country to avoid an over- and underuse
of statins for primary prevention.
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